Topic: Middle East respiratory syndrome
IDT Biologika has a new human vaccine manufacturing facility as its narrows its focus to the development and production of human vaccines only.
Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.
Inovio and GeneOne have started a clinical study of their MERS vaccine in South Korea, where the virus took 36 lives in a 2015 outbreak.
With new IVI funding, Inovio plans to ratchet up research on its MERS vaccine, the only candidate against the virus now under testing in humans.
With an eye on an "emergent global health concern," GeneOne Life Science teamed up with the Walter Reed Army Institute of Research this week to usher its vaccine for Middle East respiratory syndrome (MERS) into a first-in-human trial at the institute.